CIK 0001563880 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Net income (USD) | -29.2 M | -33.9 M | ||
| Diluted EPS (USD/shares) | -0.32 | -0.29 | -0.45 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-17 | 4 | 4 | 2026-09-15 |
| 2026-09-15 | 144 | 144 | |
| 2026-08-06 | S-8 | S-8 | |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-08-06 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-06-04 | 4 | 4 | 2026-06-03 |
| 2026-06-04 | 8-K | 8-K items 5.03,5.07,9.01 | 2026-06-03 |
| 2026-06-04 | 4 | 4 | 2026-06-03 |
| 2026-06-04 | 4 | 4 | 2026-06-03 |
| 2026-06-04 | 4 | 4 | 2026-06-03 |
| 2026-06-04 | 4 | 4 | 2026-06-03 |
| 2026-05-07 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-05-06 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-05 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-05 | 8-K | 8-K items 2.02,9.01 | 2026-05-05 |
| 2026-04-21 | DEF 14A | DEF 14A | 2026-04-21 |
| 2026-04-21 | DEFA14A | DEFA14A | |
| 2026-04-21 | ARS | ARS | 2025-12-31 |
| 2026-04-17 | 424B5 | 424B5 | |
| 2026-04-17 | 8-K | 8-K items 1.01,2.02,8.01,9.01 | 2026-04-16 |
| 2026-04-16 | 424B5 | 424B5 | |
| 2026-04-10 | PRE 14A | PRE 14A | 2026-04-10 |
| 2026-03-27 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-03-17 | 10-K | 10-K | 2025-12-31 |
Forms on file (last 1,000): 4 198, 8-K 80, 3 43, 10-Q 23, SC 13G/A 19, SCHEDULE 13G/A 14, 144 13, SC 13G 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=TRVI (0.002 USD), /gw/filings/filings?ticker=TRVI&form=8-K, /gw/filings/facts?ticker=TRVI&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange